AcelRx Pharmaceuticals Inc. (ACRX)’s Financial Results Comparing With ABIOMED Inc. (NASDAQ:ABMD)

As Medical Appliances & Equipment businesses, AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and ABIOMED Inc. (NASDAQ:ABMD), are affected by contrast. This especially applies to their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AcelRx Pharmaceuticals Inc. 2.07M 91.74 49.23M -0.76 0.00
ABIOMED Inc. 769.43M 15.03 259.02M 5.61 46.28

Demonstrates AcelRx Pharmaceuticals Inc. and ABIOMED Inc. earnings per share, gross revenue and valuation.


Table 2 represents AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and ABIOMED Inc. (NASDAQ:ABMD)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
AcelRx Pharmaceuticals Inc. -2,378.26% 137.5% -54.1%
ABIOMED Inc. 33.66% 24.9% 22.1%

Volatility & Risk

A beta of 2.27 shows that AcelRx Pharmaceuticals Inc. is 127.00% more volatile than Standard and Poor’s 500. ABIOMED Inc. on the other hand, has 0.35 beta which makes it 65.00% less volatile compared to Standard and Poor’s 500.


AcelRx Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 6.8 and 6.7 respectively. The Current Ratio and Quick Ratio of its competitor ABIOMED Inc. are 6.8 and 6 respectively. therefore has a better chance of paying off short and long-term obligations compared to .

Analyst Ratings

Ratings and Recommendations for AcelRx Pharmaceuticals Inc. and ABIOMED Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AcelRx Pharmaceuticals Inc. 0 0 5 3.00
ABIOMED Inc. 0 0 1 3.00

The average price target of AcelRx Pharmaceuticals Inc. is $8.5, with potential upside of 252.70%. On the other hand, ABIOMED Inc.’s potential upside is 79.87% and its average price target is $461. The data provided earlier shows that AcelRx Pharmaceuticals Inc. appears more favorable than ABIOMED Inc., based on analyst view.

Institutional and Insider Ownership

Institutional investors owned 17.9% of AcelRx Pharmaceuticals Inc. shares and 89.5% of ABIOMED Inc. shares. About 1.7% of AcelRx Pharmaceuticals Inc.’s share are owned by insiders. On the other hand, insiders owned about 1.8% of ABIOMED Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AcelRx Pharmaceuticals Inc. -11.97% -9.65% 20.7% -5.79% 23.6% 33.77%
ABIOMED Inc. -0.23% -4.63% -28.17% -35.91% -30.88% -20.11%

For the past year AcelRx Pharmaceuticals Inc. has 33.77% stronger performance while ABIOMED Inc. has -20.11% weaker performance.


On 7 of the 11 factors ABIOMED Inc. beats AcelRx Pharmaceuticals Inc.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is approved in the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory; and is under development stage in the United States. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.